Humana hits highest share price ever

With a stake in two post-acute care companies under its belt, health insurer Humana saw its share price hit a new record high last week.

Louisville-based Humana’s share price topped $317 on Friday, July 13, just a few days after the company finalized its previously announced acquisitions of Kindred Healthcare, the nation’s largest home health care provider, and Curo Health Services, a hospice provider in 22 states.

Under terms of the separate deals, Humana acquired a 40 percent stake in Kindred’s home health business, Kindred at Home, for $800 million, with private equity firms TPG Capital and Welsh, Carson, Anderson & Stowe owning the remaining 60 percent. Humana also acquired a 40 percent stake in Curo, with the private equity partners owning the remaining 60 percent.

Investors have further confidence in the company as a result of Humana’s recent deals as well as “positive forecasts for federal policy,” Louisville Business First reported.

Humana’s share price was trading above $317 again on the afternoon of Wednesday, July 18.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”